A Phase 2 interventional study of LY3471851 and Placebo in Colitis, Ulcerative, sponsored by Nektar Therapeutics. Terminated at 116 sites in 22 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-05.
Sponsored by Nektar Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 123 studies in Colitis, Ulcerative with a site in Japan — 23 open to participants now, 48 under way, 25 of them phase 3. Colitis, Ulcerative · Japan.
Among the 123 studies in Colitis, Ulcerative with a site in Japan, this one is the 85th largest by enrollment of the 110 interventional ones that give a count, is one of 11 that started in 2021, is one of 39 in phase 2, and was the 62nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →23 of the 123 studies in Colitis, Ulcerative with a site in Japan are open now. Recruiting first, the newest first:
AbbVie · Sites in Japan, United States, Canada and 2 more countries
Ages 18–75
Metagen Therapeutics, Inc. · Sites in Japan, United States
Ages 18–75
Pfizer · Sites in Japan, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in Japan, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Japan, United States, Argentina and 25 more countries
Ages 18–80
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 48 · Phase 3 64 · Phase 4 4
First in 2006; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 206 across the 110 interventional studies, 308 across the 13 observational. Of the 75 that completed or were terminated, 53 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 123 have an industry lead sponsor. The 10 most frequent:
Nektar Therapeutics is the lead sponsor of 39 studies on the registry; 2 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 13 (59%) have results posted.
Nektar Therapeutics has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
13 of the studies in Colitis, Ulcerative with a site in Japan that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
Add all 13 to your calendar (.ics) → With an account.
Among the 123 studies in Colitis, Ulcerative with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.
In stage 1, two doses (high and low) of LY3471851 will be compared to placebo. In stage 2, up to two additional doses (to be confirmed) of LY3471851 will be compared to placebo.
LY3471851 (NKTR-358) is a potential first-in-class therapeutic that may address an underlying immune system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. By activating these cells, LY3471851 may act to bring the immune system back into balance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a subcutaneous injection of high dose LY3471851 every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
Drug: LY3471851
Participants received a subcutaneous injection of low dose LY3471851 every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
Drug: LY3471851
Participants received a subcutaneous injection of placebo every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
Drug: LY3471851 · Drug: Placebo
administered SC
Also known as: NKTR-358
administered SC
Percentage of Participants Who Achieved Clinical Remission at Week 12
Clinical remission is defined as achieving a Modified Mayo Score (MMS) sub-score for rectal bleeding=0, stool frequency=0, or stool frequency=1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability). The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
Time frame: Week 12
Percentage of Participants Who Achieved Clinical Response at Week 12
Clinical response is defined as a decrease in the MMS of ≥2 points and ≥30% decrease from baseline, and a decrease of ≥1 point in the rectal bleeding sub-score from baseline or a rectal bleeding score of 0 or 1. The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
Time frame: Week 12
Percentage of Participants Who Achieved Endoscopic Remission at Week 12
Endoscopic remission is defined as achieving a MMS sub-score for endoscopy=0 or 1 (excluding friability). The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
Time frame: Week 12
Percentage of Participants Who Achieved Endoscopic Response at Week 12
Endoscopic response is defined as a decrease of ≥1 point in the MMS endoscopy sub-score from baseline. The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
Time frame: Week 12
Percentage of Participants Who Achieved Symptomatic Remission at Week 12
Symptomatic remission is defined as achieving a MMS sub-score for stool frequency=0, or stool frequency=1 with a decrease of ≥1 point from baseline, and rectal bleeding =0. The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
Time frame: Week 12
Percentage of Participants Who Achieved Symptomatic Response at Week 12
Symptomatic response is defined as a ≥30% decrease from baseline in the composite clinical endpoint of the sum of MMS sub-scores of stool frequency and rectal bleeding. The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
Time frame: Week 12
Percentage of Participants Who Achieved Histologic Remission at Week 12
Histologic Remission is defined as Geboes score \<2 or subscores = 0 for Grade 2a, 2b, 3, 4, and 5. The Geboes score is a 7-item instrument used to identify histologic changes in UC. The 7 items are Grade 0: Architectural changes (0=No abnormality to 3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (0=No increase to 3=Marked increase); Grade 2A: lamina propria eosinophils (0=No increase to 3=Marked increase); Grade 2B: lamina propria neutrophils (0= No increase to 3=Marked increase); Grade 3: Neutrophils in epithelium (0=None to 3=\>50% crypts involved); Grade 4: Crypt destruction(0=none to 3=Unequivocal crypt destruction),and Grade 5: Erosion or ulceration:(0=No erosion, ulceration or granulation to 4=Ulcer or granulation tissue). The grade with severe histological observation is considered the Geboes score and ranges from 0 to 4, with higher scores indicating severe disease.
Time frame: Week 12
Percentage of Participants Who Achieved Histologic-Endoscopic Mucosal Healing (HEMH)
HEMH is defined as Geboes score \<2 AND endoscopic remission. Geboes score is a 7-item instrument used to identify histologic changes in UC. The 7-items are Grade 0: Architectural changes (0=No abnormality to 3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (0=No increase to 3=Marked increase); Grade 2A: lamina propria eosinophils (0=No increase to 3=Marked increase); Grade 2B: lamina propria neutrophils (0= No increase to 3=Marked increase); Grade 3: Neutrophils in epithelium (0=None to 3=\>50% crypts involved); Grade 4: Crypt destruction(0=none to 3=Unequivocal crypt destruction),and Grade 5: Erosion or ulceration:(0=No erosion, ulceration or granulation to 4=Ulcer or granulation tissue). The grade with severe histological observation is considered the Geboes score and ranges from 0 to 4, with higher scores indicating severe disease. Endoscopic remission is defined as achieving a MMS sub-score for endoscopy=0 or 1 (excluding friability).
Time frame: Week 12
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) - Total Score
IBDQ is a 32-item questionnaire that measures four aspects of participants' lives: symptoms directly related to the primary bowel disturbance (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Responses are graded on a 7-point Likert scale, where 7 denotes "not a problem at all" and 1 denotes "a very severe problem." The responses are summed to produce a total score ranging from 32 to 224, with higher score indicating a better quality of life. LS Mean was calculated using ANCOVA (analysis of covariance) model with treatment, baseline value, previous advanced therapy failure status (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4 to 6\] or \[7 to 9\]) and region (North America/Europe/Other) as fixed factors.
Time frame: Baseline, Week 12
Pharmacokinetics (PK): Trough Concentration of LY3471851 (Ctrough) at Week 12
C-trough is the concentration of drug in the blood immediately before the next dose was administered.
Time frame: Predose at week 12
The study consisted of: * a 12-week induction treatment period: participants randomly received either high dose LY3471851 or low dose LY3471851 or placebo. * a 40-week maintenance/extension treatment period (final dose at week 50 and study assessments at week 52) * (i) Week 12 responders enter the maintenance period where they continued to receive the same treatment to which they were randomly assigned. (Continued..)
| Milestone | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | High Dose LY3471851 (Maintenance Treatment Period) | Low Dose LY3471851 (Maintenance Treatment Period) | Placebo (Maintenance Treatment Period) | High Dose LY3471851 (Extension Treatment Period) | High Dose LY3471851 (Post-Treatment Follow-up Period) | Low Dose LY3471851 (Post-Treatment Follow-up Period) | Placebo (Post-Treatment Follow-up Period) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 32 | 35 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 32 | 35 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 19 | 22 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 13 | 13 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 7 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | High Dose LY3471851 (Maintenance Treatment Period) | Low Dose LY3471851 (Maintenance Treatment Period) | Placebo (Maintenance Treatment Period) | High Dose LY3471851 (Extension Treatment Period) | High Dose LY3471851 (Post-Treatment Follow-up Period) | Low Dose LY3471851 (Post-Treatment Follow-up Period) | Placebo (Post-Treatment Follow-up Period) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 8 | 10 | 5 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 8 | 10 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 7 | 9 | 5 | 0 | 0 | 0 | 0 |
| Milestone | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | High Dose LY3471851 (Maintenance Treatment Period) | Low Dose LY3471851 (Maintenance Treatment Period) | Placebo (Maintenance Treatment Period) | High Dose LY3471851 (Extension Treatment Period) | High Dose LY3471851 (Post-Treatment Follow-up Period) | Low Dose LY3471851 (Post-Treatment Follow-up Period) | Placebo (Post-Treatment Follow-up Period) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 0 | 0 | 0 |
| Milestone | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | High Dose LY3471851 (Maintenance Treatment Period) | Low Dose LY3471851 (Maintenance Treatment Period) | Placebo (Maintenance Treatment Period) | High Dose LY3471851 (Extension Treatment Period) | High Dose LY3471851 (Post-Treatment Follow-up Period) | Low Dose LY3471851 (Post-Treatment Follow-up Period) | Placebo (Post-Treatment Follow-up Period) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 30 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 30 | 11 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 26 | 11 |
Clinical remission is defined as achieving a Modified Mayo Score (MMS) sub-score for rectal bleeding=0, stool frequency=0, or stool frequency=1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability). The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
| percentage of participants | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission at Week 12 | 14.3 (0 to 32.6) | 7.1 (0 to 16.7) | 17.2 (3.5 to 31) |
Clinical response is defined as a decrease in the MMS of ≥2 points and ≥30% decrease from baseline, and a decrease of ≥1 point in the rectal bleeding sub-score from baseline or a rectal bleeding score of 0 or 1. The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
| percentage of participants | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Response at Week 12 | 35.7 (10.6 to 60.8) | 39.3 (21.2 to 57.4) | 41.4 (23.5 to 59.3) |
Endoscopic remission is defined as achieving a MMS sub-score for endoscopy=0 or 1 (excluding friability). The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
| percentage of participants | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Percentage of Participants Who Achieved Endoscopic Remission at Week 12 | 28.6 (4.9 to 52.2) | 14.3 (1.3 to 27.2) | 24.1 (8.6 to 39.7) |
Endoscopic response is defined as a decrease of ≥1 point in the MMS endoscopy sub-score from baseline. The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
| percentage of participants | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Percentage of Participants Who Achieved Endoscopic Response at Week 12 | 21.4 (0 to 42.9) | 32.1 (14.8 to 49.4) | 37.9 (20.3 to 55.6) |
Symptomatic remission is defined as achieving a MMS sub-score for stool frequency=0, or stool frequency=1 with a decrease of ≥1 point from baseline, and rectal bleeding =0. The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
| percentage of participants | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Percentage of Participants Who Achieved Symptomatic Remission at Week 12 | 21.4 (0 to 42.9) | 32.1 (14.8 to 49.4) | 27.6 (11.3 to 43.9) |
Symptomatic response is defined as a ≥30% decrease from baseline in the composite clinical endpoint of the sum of MMS sub-scores of stool frequency and rectal bleeding. The MMS is a scoring system for assessment of UC and is composed of sub-scores of stool frequency (range: 0 to 3, where 0=normal number of stools, 3=5 or more stools more than normal), endoscopy (range: 0 to 3, where 0=normal or inactive disease, 3=severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0=no blood seen, 3=blood alone passed). Total MMS score is sum of all sub-scores and ranges from 0 to 9, with higher scores indicating higher disease activity.
| percentage of participants | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Percentage of Participants Who Achieved Symptomatic Response at Week 12 | 42.9 (16.9 to 68.8) | 42.9 (24.5 to 61.2) | 44.8 (26.7 to 62.9) |
Histologic Remission is defined as Geboes score \<2 or subscores = 0 for Grade 2a, 2b, 3, 4, and 5. The Geboes score is a 7-item instrument used to identify histologic changes in UC. The 7 items are Grade 0: Architectural changes (0=No abnormality to 3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (0=No increase to 3=Marked increase); Grade 2A: lamina propria eosinophils (0=No increase to 3=Marked increase); Grade 2B: lamina propria neutrophils (0= No increase to 3=Marked increase); Grade 3: Neutrophils in epithelium (0=None to 3=\>50% crypts involved); Grade 4: Crypt destruction(0=none to 3=Unequivocal crypt destruction),and Grade 5: Erosion or ulceration:(0=No erosion, ulceration or granulation to 4=Ulcer or granulation tissue). The grade with severe histological observation is considered the Geboes score and ranges from 0 to 4, with higher scores indicating severe disease.
| percentage of participants | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Percentage of Participants Who Achieved Histologic Remission at Week 12 | 7.1 (0.0 to 20.6) | 7.1 (0.0 to 16.7) | 10.3 (0.0 to 21.4) |
HEMH is defined as Geboes score \<2 AND endoscopic remission. Geboes score is a 7-item instrument used to identify histologic changes in UC. The 7-items are Grade 0: Architectural changes (0=No abnormality to 3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (0=No increase to 3=Marked increase); Grade 2A: lamina propria eosinophils (0=No increase to 3=Marked increase); Grade 2B: lamina propria neutrophils (0= No increase to 3=Marked increase); Grade 3: Neutrophils in epithelium (0=None to 3=\>50% crypts involved); Grade 4: Crypt destruction(0=none to 3=Unequivocal crypt destruction),and Grade 5: Erosion or ulceration:(0=No erosion, ulceration or granulation to 4=Ulcer or granulation tissue). The grade with severe histological observation is considered the Geboes score and ranges from 0 to 4, with higher scores indicating severe disease. Endoscopic remission is defined as achieving a MMS sub-score for endoscopy=0 or 1 (excluding friability).
| percentage of participants | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Percentage of Participants Who Achieved Histologic-Endoscopic Mucosal Healing (HEMH) | 0 (0 to 0) | 3.6 (0 to 10.4) | 6.9 (0 to 16.1) |
IBDQ is a 32-item questionnaire that measures four aspects of participants' lives: symptoms directly related to the primary bowel disturbance (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Responses are graded on a 7-point Likert scale, where 7 denotes "not a problem at all" and 1 denotes "a very severe problem." The responses are summed to produce a total score ranging from 32 to 224, with higher score indicating a better quality of life. LS Mean was calculated using ANCOVA (analysis of covariance) model with treatment, baseline value, previous advanced therapy failure status (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4 to 6\] or \[7 to 9\]) and region (North America/Europe/Other) as fixed factors.
| score on a scale | Placebo (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|---|
| Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) - Total Score | 26.71 ± 9.346 | 36.42 ± 7.640 | 25.76 ± 7.143 |
C-trough is the concentration of drug in the blood immediately before the next dose was administered.
| microgram per milliliter (µg/mL) | Low Dose LY3471851 (Induction Treatment Period) | High Dose LY3471851 (Induction Treatment Period) |
|---|---|---|
| Pharmacokinetics (PK): Trough Concentration of LY3471851 (Ctrough) at Week 12 | 91.3 ± 49 | 139 ± 105 |
Collected over Baseline to Follow-up (Up To Week 58). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Dose LY3471851 (Induction Treatment Period) | 0/32 (0%) | 2/32 (6.3%) | 20/32 (62.5%) |
| Low Dose LY3471851 (Induction Treatment Period) | 0/35 (0%) | 0/35 (0%) | 15/35 (42.9%) |
| Placebo (Induction Treatment Period) | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| High Dose LY3471851 (Maintenance Treatment Period) | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Low Dose LY3471851 (Maintenance Treatment Period) | 0/10 (0%) | 1/10 (10%) | 6/10 (60%) |
| Placebo (Maintenance Treatment Period) | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| High Dose LY3471851 (Extension Treatment Period) | 0/26 (0%) | 0/26 (0%) | 5/26 (19.2%) |
| High Dose LY3471851 (Post-Treatment Follow-up Period) | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) |
| Low Dose LY3471851 (Post-Treatment Follow-up Period) | 0/30 (0%) | 1/30 (3.3%) | 1/30 (3.3%) |
| Placebo (Post-Treatment Follow-up Period) | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Event | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | High Dose LY3471851 (Maintenance Treatment Period) | Low Dose LY3471851 (Maintenance Treatment Period) | Placebo (Maintenance Treatment Period) | High Dose LY3471851 (Extension Treatment Period) | High Dose LY3471851 (Post-Treatment Follow-up Period) | Low Dose LY3471851 (Post-Treatment Follow-up Period) | Placebo (Post-Treatment Follow-up Period) |
|---|---|---|---|---|---|---|---|---|---|---|
| Vulval abscessInfections and infestations | 0/32 | 0/35 | 0/14 | 0/8 | 1/10 | 0/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/32 | 0/35 | 0/14 | 0/8 | 0/10 | 0/5 | 0/26 | 0/25 | 1/30 | 0/11 |
| ProctitisGastrointestinal disorders | 1/32 | 0/35 | 0/14 | 0/8 | 0/10 | 0/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| SyncopeNervous system disorders | 1/32 | 0/35 | 0/14 | 0/8 | 0/10 | 0/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| Event | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | High Dose LY3471851 (Maintenance Treatment Period) | Low Dose LY3471851 (Maintenance Treatment Period) | Placebo (Maintenance Treatment Period) | High Dose LY3471851 (Extension Treatment Period) | High Dose LY3471851 (Post-Treatment Follow-up Period) | Low Dose LY3471851 (Post-Treatment Follow-up Period) | Placebo (Post-Treatment Follow-up Period) |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 8/32 | 6/35 | 0/14 | 1/8 | 0/10 | 0/5 | 2/26 | 0/25 | 0/30 | 0/11 |
| PyrexiaGeneral disorders | 7/32 | 2/35 | 1/14 | 2/8 | 1/10 | 0/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| Covid-19Infections and infestations | 2/32 | 3/35 | 1/14 | 1/8 | 0/10 | 1/5 | 2/26 | 0/25 | 0/30 | 0/11 |
| NasopharyngitisInfections and infestations | 0/32 | 0/35 | 0/14 | 1/8 | 0/10 | 1/5 | 0/26 | 0/25 | 1/30 | 0/11 |
| TonsillitisInfections and infestations | 0/32 | 0/35 | 0/14 | 0/8 | 0/10 | 1/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| SyncopeNervous system disorders | 0/32 | 0/35 | 0/14 | 0/8 | 0/10 | 1/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| MalaiseGeneral disorders | 0/32 | 0/35 | 0/14 | 1/8 | 0/10 | 0/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| Injection related reactionInjury, poisoning and procedural complications | 0/32 | 0/35 | 0/14 | 1/8 | 1/10 | 0/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| Body temperature increasedInvestigations | 4/32 | 0/35 | 0/14 | 1/8 | 0/10 | 0/5 | 0/26 | 0/25 | 0/30 | 0/11 |
| HeadacheNervous system disorders | 4/32 | 1/35 | 0/14 | 0/8 | 0/10 | 0/5 | 0/26 | 0/25 | 0/30 | 0/11 |
All randomized participants.
| Age, Continuous(years) | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | Total |
|---|---|---|---|---|
| Mean | 39.2 ± 12.5 | 44.5 ± 13.8 | 45.7 ± 15.2 | 42.6 ± 13.7 |
| Sex: Female, Male(Participants) | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | Total |
|---|---|---|---|---|
| Female | 10 | 9 | 6 | 25 |
| Male | 22 | 26 | 8 | 56 |
| Race (NIH/OMB)(Participants) | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 5 | 4 | 2 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 2 |
| White | 25 | 31 | 12 | 68 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | High Dose LY3471851 (Induction Treatment Period) | Low Dose LY3471851 (Induction Treatment Period) | Placebo (Induction Treatment Period) | Total |
|---|---|---|---|---|
| Argentina | 2 | 1 | 1 | 4 |
| Australia | 0 | 1 | 0 | 1 |
| Belgium | 0 | 0 | 1 | 1 |
| Czechia | 2 | 4 | 0 | 6 |
| Hungary | 3 | 3 | 0 | 6 |
| Japan | 3 | 1 | 1 | 5 |
| South Korea | 1 | 3 | 1 | 5 |
| Latvia | 2 | 3 | 0 | 5 |
| Poland | 2 | 2 | 1 | 5 |
| Russia | 5 | 5 | 3 | 13 |
| Slovakia | 1 | 1 | 1 | 3 |
| Ukraine | 7 | 7 | 4 | 18 |
| United States | 3 | 4 | 1 | 8 |
Showing the first 100 of 116 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Aug 2022, 16 months.
Results were first posted in Sep 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rezpegaldesleukin